REYON Pharmaceutical Co., Ltd.

KOSE:A102460 Stok Raporu

Piyasa değeri: ₩286.7b

REYON Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for REYON Pharmaceutical.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi38.2%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

None

Son güncellemen/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

REYON Pharmaceutical Co., Ltd.'s (KRX:102460) Shareholders Might Be Looking For Exit

Oct 18
REYON Pharmaceutical Co., Ltd.'s (KRX:102460) Shareholders Might Be Looking For Exit

There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings

Mar 31
There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings

Consider This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For The 1.6% Dividend

May 08
Consider This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For The 1.6% Dividend

Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden

Apr 09
Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden

What Percentage Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Shares Do Insiders Own?

Feb 28
What Percentage Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Shares Do Insiders Own?

Read This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For Its Dividend

Jan 20
Read This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For Its Dividend

REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly

Jan 02
REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly

Did REYON Pharmaceutical's (KRX:102460) Share Price Deserve to Gain 50%?

Dec 12
Did REYON Pharmaceutical's (KRX:102460) Share Price Deserve to Gain 50%?

How Much Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Do Insiders Own?

Nov 24
How Much Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Do Insiders Own?

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak REYON Pharmaceutical yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

KOSE:A102460 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (KRW Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
6/30/2024148,991-104-22,2252,657N/A
3/31/2024151,0561,902-20,6094,252N/A
12/31/2023151,0713,583-20,2278,645N/A
9/30/2023150,5848,456-19,03812,971N/A
6/30/2023152,04310,614-21,68612,848N/A
3/31/2023153,9077,503-32,9119,962N/A
12/31/2022154,0397,359-54,4048,729N/A
9/30/2022152,5494,816-63,9499,463N/A
6/30/2022150,2372,774-82,04212,848N/A
3/31/2022146,3296,265-103,33115,345N/A
12/31/2021142,8015,412-105,31211,685N/A
9/30/2021139,4145,650-107,7138,450N/A
6/30/2021135,8936,518-93,9095,607N/A
3/31/2021131,3034,843-70,2652,981N/A
12/31/2020130,0343,844-47,2874,599N/A
9/30/2020129,7381,720-39,6992,314N/A
6/30/2020129,6842,165-35,3376,798N/A
3/31/2020131,5812,165-53,806-12,825N/A
12/31/2019131,5584,946-63,564-12,184N/A
9/30/2019128,2671,478-56,438-5,595N/A
6/30/2019125,963594-74,593-12,861N/A
3/31/2019124,1923,299-47,7905,730N/A
12/31/2018122,9901,343-27,74811,449N/A
9/30/2018122,8507,021-25,0258,456N/A
6/30/2018123,9369,6432,58411,159N/A
3/31/2018124,1509,073N/A15,186N/A
12/31/2017126,25312,887N/A16,764N/A
9/30/2017126,74813,195N/A14,348N/A
12/31/2016121,84710,701N/A9,471N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if A102460's forecast earnings growth is above the savings rate (2.6%).

Kazançlar ve Piyasa: Insufficient data to determine if A102460's earnings are forecast to grow faster than the KR market

Yüksek Büyüme Kazançları: Insufficient data to determine if A102460's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if A102460's revenue is forecast to grow faster than the KR market.

Yüksek Büyüme Geliri: Insufficient data to determine if A102460's revenue is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if A102460's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin